新生血管性(湿性)年龄相关性黄斑变性与糖尿病性黄斑水肿的治疗药物——法瑞西单抗  

A therapeutic drug for the treatment of neovascular(wet)age-related macular degeneration and diabetic macular edema:faricimab

作　　者：白嘎力 张姣[1,2] 文睿婷 BAI Ga-li;ZHANG Jiao;WEN Rui-ting(Department of Pharmacy,People's Hospital of Peking University,Beijing 100044,China;Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China)

机构地区：[1]北京大学人民医院药学部,北京100044 [2]北京大学药学院药事管理与临床药学系,北京100191

出　　处：《临床药物治疗杂志》2023年第4期11-15,共5页Clinical Medication Journal

摘　　要：法瑞西单抗是一种双特异性抗体,可特异性抑制血管内皮生长因子-A(VEGF-A)和血管生成素-2(Ang-2),通过双途径作用提高疗效并延长给药间隔,用于治疗新生血管性(湿性)年龄相关性黄斑变性(nAMD)和糖尿病性黄斑水肿(DME)。法瑞西单抗于2022年1月28日在美国获批,随后在日本、英国、加拿大等国家获批上市。本文对法瑞西单抗的药理作用、药动学特点、临床疗效和安全性等进行综述,旨在为临床应用提供参考。Faricimab is a bispecific antibody that specifically inhibits vascular endothelial growth factor-A(VEGF-A)and angiopoietin-2(Ang-2)which can enhance efficacy and extend the administration interval.It is used to treat neovascular(wet)age-related macular degeneration(nAMD)and diabetic macular edema(DME).Faricimab was approved in the United States on January 28,2022,and was subsequently approved in Japan,the United Kingdom and Canada.This article provides an overview of the pharmacological mechanism,pharmacokinetic characteristics,clinical efficacy and safety of faricimab to provide reference for its clinical application.

关 键 词：法瑞西单抗 年龄相关性黄斑变性 糖尿病性黄斑水肿 

分 类 号：R988.1[医药卫生—药品]